Recent Clinical Progress in Ovarian Cancer

Robert Coleman, MD and Robert Figlin, MD, discuss the evolving role of bevacizumab in ovarian cancer, recently presented clinical studies such as BOOST and EFFORT, and the challenge of treating the PARP-refractory setting in advanced ovarian cancer.